Because serological testing is easily performed, inexpensive, and informative about GC risk, in this study we evaluated changes in serological HP and CagA antibody titers and endoscopic atrophy after HPE in the effort to identify risk factors for post-HPE GC development. This evidence concerns the gene S100A8 and Atrophy.